Zacks Research downgraded Gyre Therapeutics from hold to strong sell on August 20, 2026. This revision signals a bearish outlook for the company’s near-term prospects.
The downgrade follows an August 7 quarterly report showing a loss of $0.12 per share. This result missed consensus estimates by $0.06.
Quarterly revenue reached $29.11 million, which surpassed analyst expectations. The broader analyst consensus for Gyre remains a Hold with a target price of $17.